Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: communication from the SSC of the ISTH

Brambilla, M; Di Minno, MND; Josefsson, EC; Lordkipanidze, M; Ramstrom, S; Di Minno, A; Gangatirkar, P; Moujalled, D; Becchetti, A; Camera, M

Author(s): Brambilla, M; Di Minno, MND; Josefsson, EC; Lordkipanidze, M; Ramstrom, S; Di Minno, A; Gangatirkar, P; Moujalled, D; Becchetti, A; Camera, M;
Details: Publication Year 2025-12,Volume 23,Issue #12,Page 3989-4009
Journal Title: Journal of Thrombosis and Haemostasis
Abstract: BACKGROUND: Given the role of platelets in coronary artery disease (CAD), assessment of a soluble platelet-activation marker may be useful to improve thrombotic risk stratification. OBJECTIVES: This study aimed to perform a meta-analysis investigating the association between levels of 14 such markers associated with CAD. METHODS: PubMed, Web of Science, and Excerpta Medica dataBASE (EMBASE) were searched until November 2024. The primary end point was the difference in levels of 11-dehydro-thromboxane B(2), 2,3-dinor-thromboxane B(2), beta-thromboglobulin, soluble CD40L (sCD40L), glycocalicin, glycoprotein (GP)V, GPVI, matrix metalloproteinase (MMP)-9 and MMP-2, platelet factor (PF)4, soluble (s) P-selectin, SCUBE1, serotonin and thrombospondin (TSP)-1 between patients with CAD and healthy subjects (HSs) in plasma and/or serum. When possible, patients with CAD were stratified into acute coronary syndrome (ACS) and chronic coronary disease. Standardized mean difference (SMD) was calculated. RESULTS: Due to heterogeneity in the assessed studies, meta-analysis was performed for sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, SCUBE1, and TSP-1. All markers but TSP-1 were significantly elevated in patients with CAD compared with HSs. Differences in sCD40L and SCUBE1 were statistically significant only when studies that assessed plasma were combined with those that assessed serum. When compared with HSs, the differences were bigger in patients with ACS than patients with chronic coronary disease for MMP-9 (SMD, 2.49 vs 0.49), PF4 (SMD, 2.01 vs 0.96), and sP-selectin (SMD, 1.81 vs 0.63). Publication bias was identified for sCD40L and, in ACS, for sP-selectin and PF4. CONCLUSION: The increased levels of sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, and SCUBE1 in patients with CAD compared with HSs provide a rationale for designing new studies to address the potential of such molecules as biomarkers for thrombotic risk stratification.
Publisher: Elsevier
Keywords: Humans; Acute Coronary Syndrome/blood/diagnosis; Biomarkers/blood; *Blood Platelets/metabolism; *Coronary Artery Disease/blood/diagnosis; P-Selectin/blood; *Platelet Activation; Predictive Value of Tests; coronary artery disease; meta-analysis; platelet activation; soluble biomarker; thrombotic risk
Research Division(s): Blood Cells and Blood Cancer
PubMed ID: 40685139
Publisher's Version: https://doi.org/10.1016/j.jtha.2025.07.014
Open Access at Publisher's Site: https://doi.org/10.1016/j.jtha.2025.07.014
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-07-28 03:09:54

Last Modified: 2025-12-15 01:28:24